Evaluation of the use of antisense oligonucleotides as a personalized therapy for Neurofibromatosis Type 2 patients

syn21355225

Created By Elisabeth Castellanos ecastellanos

grantDOI: https://doi.org/10.48105/pc.gr.90471
studyName: Evaluation of the use of antisense oligonucleotides as a personalized therapy for Neurofibromatosis Type 2 patients
dataStatus: Under Embargo
initiative: Drug Discovery Initiative Registered Reports
studyLeads: Núria Catasús Sandra Bonache Belen García Adrià Plana Hector Salvador Isabel Bielsa Eduard Serra Ignacio Blanco Elisabeth Castellanos
studyStatus: Completed
diseaseFocus: Neurofibromatosis type 2
grantEndDate: 1656547200000
institutions: Germans Trias I Pujol Research Institute (IGTP) Hospital Universitari Germans Trias i Pujol (HUGTP)
fundingAgency: CTF
embargoEndDate: 1690675200000
grantStartDate: 1593561600000
relatedStudies: syn21642010 syn26383473 syn51907739 syn35632706
studyFileviewId: syn25999949
syn25999947
syn30261992
syn35584441
syn25999949
syn64376801
syn64420236

Your web browser must have JavaScript enabled in order for this application to display correctly.
If you are an automated web crawler from a search engine, follow this AJAX application crawl link

Evaluation of the use of antisense oligonucleotides as a personalized therapy for Neurofibromatosis Type 2 patients

syn21355225

Drop files to upload

Evaluation of the use of antisense oligonucleotides as a personalized therapy for Neurofibromatosis Type 2 patients page is loading…